Lisata Therapeutics, Inc (LSTA) insider trading

Every open-market stock purchase and sale by Lisata Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.

Insider activity at a glance

  • No open-market insider trades in the last 12 months.
  • No open-market insider buys on record.

Last 12 months: insiders bought $0 (0 buys) and sold $0 (0 sales). Last close $1.00 on Oct 22, 2026.

Recent LSTA insider trades

DateInsiderTradeValue
Jan 9, 2026David J Mazzo (CEO)Sold (not open market)$24.1K
Jan 9, 2026David J Mazzo (CEO)Sold (not open market)$20.7K
Jan 9, 2026David J Mazzo (CEO)Sold (not open market)$20.7K
Jan 9, 2026David J Mazzo (CEO)Sold (not open market)$15.5K
Jan 9, 2026Kristen K Buck (C-suite exec)Sold (not open market)$6.3K
Jan 9, 2026Kristen K Buck (C-suite exec)Sold (not open market)$5.9K
Jan 9, 2026Kristen K Buck (C-suite exec)Sold (not open market)$4.2K
Jan 9, 2026James Nisco (VP)Sold (not open market)$4.2K
Jan 9, 2026Tariq Imam (VP)Sold (not open market)$2.8K
Jan 9, 2026James Nisco (VP)Sold (not open market)$2.2K
Jan 9, 2026Tariq Imam (VP)Sold (not open market)$1.7K
Jan 9, 2026James Nisco (VP)Sold (not open market)$1.5K
Jan 9, 2026Tariq Imam (VP)Sold (not open market)$1.5K
Jan 9, 2026Tariq Imam (VP)Sold (not open market)$1K
Jan 9, 2026Mohammad Azab (Director)Bought (not open market)—
Jan 9, 2026Cynthia Louise Flowers (Director)Bought (not open market)—
Jan 9, 2026David J Mazzo (CEO)Bought (not open market)—
Jan 9, 2026David J Mazzo (CEO)Bought (not open market)—
Jan 9, 2026Steven M Klosk (Director)Bought (not open market)—
Jan 9, 2026Kristen K Buck (C-suite exec)Bought (not open market)—
Jan 9, 2026James Nisco (VP)Bought (not open market)—
Jan 9, 2026Tariq Imam (VP)Bought (not open market)—
Jan 9, 2026Gregory B Brown (Director)Bought (not open market)—
Jan 9, 2026Kristen K Buck (C-suite exec)Bought (not open market)—
Jan 9, 2026Heidi Henson (Director)Bought (not open market)—

Who's trading LSTA

Get free alerts when an insider at Lisata Therapeutics, Inc files a new trade →